AR035786A2 - Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen - Google Patents
Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienenInfo
- Publication number
- AR035786A2 AR035786A2 ARP020101003A ARP020101003A AR035786A2 AR 035786 A2 AR035786 A2 AR 035786A2 AR P020101003 A ARP020101003 A AR P020101003A AR P020101003 A ARP020101003 A AR P020101003A AR 035786 A2 AR035786 A2 AR 035786A2
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- vitamin
- gla domain
- protein
- modified gla
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 9
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 9
- 101800004937 Protein C Proteins 0.000 abstract 8
- 101800001700 Saposin-D Proteins 0.000 abstract 8
- 102400000827 Saposin-D Human genes 0.000 abstract 8
- 229930003448 Vitamin K Natural products 0.000 abstract 8
- 150000001413 amino acids Chemical class 0.000 abstract 8
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract 8
- 229960000856 protein c Drugs 0.000 abstract 8
- 235000019168 vitamin K Nutrition 0.000 abstract 8
- 239000011712 vitamin K Substances 0.000 abstract 8
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract 8
- 229940046010 vitamin k Drugs 0.000 abstract 8
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 2
- 108010023321 Factor VII Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940012413 factor vii Drugs 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 230000009852 coagulant defect Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen: polipéptidos dependientes de vitamina K que incluye un dominio GLA modificado que aumenta la afinidad de unión del polipéptido con las membranas con respecto al correspondiente polipéptido nativo dependiente de vitamina K. El dominio GLA modificado puede incluir por lo menos una sustitución de amino ácido. Por ejemplo, la sustitución de amino ácido puede ser en el amino ácido 11, 12, 29, 33 o 34. El dominio GLA modificado, puede incluir una secuencia de amino ácidos que, en el estado saturado de calcio, forma una estructura terciaria que tiene un núcleo catiónico con un halo de carga electro-negativa. El polipéptido dependiente de vitamina K, puede ser por ejemplo, proteína C, proteína C actividad, factor IX, factor IXa, factor VII, factor VIIa o factor VIIa de sitio activo modificado. El dominio GLA modificado de la proteína C o la proteína C activada puede incluir un residuo ácido glutámico en el amino ácido 33 y un residuo ácido aspártico en el amino ácido 34. El dominio GLA modificado de la proteína C o de la proteína C activada, puede también incluir un residuo glutamina o ácido glutámico en el amino ácido 11. Adicionalmente, un residuo glicina puede ser sustituido en el amino ácido 12 en el dominio GLA de la proteína C o de la proteína C activada. El dominio GLA modificado del factor VII, el factor VIIa y el factor VIIa de sitio activo modificado puede contener una sustitución en el amino ácido 11 y 33. Por ejemplo, un residuo glutamina en el amino ácido 11 y un residuo ácido glutámico en el amino ácido 33, pueden estar sustituidos. Un ácido nucleico aislado que codifica una polipéptido dependiente de vitamina K que contiene un dominio GLA modificado tal como se describe arriba. Además, la presente se refiere también a una célula hospedante de mamífero que incluye un vector ácido nucleico que codifica un polipéptido dependiente de vitamina K que contiene un dominio GLA modificado según se describe arriba. Una composición farmacéutica que incluye un vehículo farmacéuticamente aceptable y una cantidad de un polipéptido dependiente de vitamina K efectiva para inhibir o incrementar la formación de coágulos en un mamífero, donde el polipéptido dependiente de vitamina K incluye un dominio GLA modificado como se ha descripto anteriormente. Un polipéptido dependiente de la vitamina K para ser utilizado en el tratamiento de una trastorno relacionado con la coagulación o en la manufactura de un medicamento para el tratamiento de un trastorno de coagulación. Métodos para incrementar o disminuir la formación de coágulos en un mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035786A2 true AR035786A2 (es) | 2004-07-14 |
Family
ID=25497114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
| ARP020101003A AR035786A2 (es) | 1997-10-23 | 2002-03-20 | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6017882A (es) |
| EP (2) | EP1090128B1 (es) |
| JP (1) | JP4276379B2 (es) |
| KR (1) | KR20010031370A (es) |
| CN (1) | CN1246462C (es) |
| AP (1) | AP2000001811A0 (es) |
| AR (2) | AR020048A1 (es) |
| AT (1) | ATE390486T1 (es) |
| AU (1) | AU749279C (es) |
| BR (1) | BR9814611A (es) |
| CA (1) | CA2307175C (es) |
| DE (1) | DE69839313T2 (es) |
| DK (1) | DK1090128T3 (es) |
| EA (1) | EA200000449A1 (es) |
| ES (2) | ES2303362T3 (es) |
| HR (1) | HRP20000234A2 (es) |
| HU (1) | HU225993B1 (es) |
| ID (1) | ID26330A (es) |
| IL (1) | IL135603A0 (es) |
| IS (1) | IS5449A (es) |
| MY (1) | MY136336A (es) |
| NO (1) | NO20002025L (es) |
| NZ (1) | NZ504114A (es) |
| PL (1) | PL194194B1 (es) |
| PT (1) | PT1090128E (es) |
| SG (1) | SG105547A1 (es) |
| TR (1) | TR200001105T2 (es) |
| TW (1) | TW587081B (es) |
| WO (1) | WO1999020767A1 (es) |
| ZA (1) | ZA989597B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| EP1237917A2 (en) * | 1999-11-19 | 2002-09-11 | Eli Lilly And Company | Protein c derivatives |
| AU2001232736A1 (en) | 2000-02-02 | 2001-08-14 | Eli Lilly And Company | Protein c derivatives |
| PL204285B1 (pl) | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| WO2001059084A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US6828306B2 (en) * | 2000-07-31 | 2004-12-07 | Ottawa Heart Institute Research Corporation | Charged lipid compositions and methods for their use |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| EP1370649A1 (en) * | 2001-03-02 | 2003-12-17 | T.A.C. Thrombosis and Coagulation AB | Protein c variants |
| WO2003073980A2 (en) * | 2002-03-01 | 2003-09-12 | T.A.C. Thrombosis And Coagulation Aktiebolag | Recombinant protein c variants |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| BR0309576A (pt) | 2002-04-30 | 2005-02-09 | Maxygen Holdings Ltd | Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| CA2490342C (en) | 2002-06-21 | 2015-06-16 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| JP4885707B2 (ja) | 2003-03-18 | 2012-02-29 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | セリンプロテアーゼを含むｇｌａ−残基の生産方法 |
| AU2004221761B2 (en) | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| DE602004025576D1 (de) * | 2003-06-19 | 2010-04-01 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
| ATE547519T1 (de) | 2003-09-09 | 2012-03-15 | Novo Nordisk Healthcare Ag | Gerinnungsfaktor-vii-polypeptide |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| EP1711513B1 (en) | 2003-12-01 | 2014-07-02 | Novo Nordisk Health Care AG | Nanofiltration of factor vii solutions to remove virus |
| ES2676644T3 (es) | 2003-12-19 | 2018-07-23 | Novo Nordisk Health Care Ag | Composiciones estabilizadas de polipéptidos de factor VII |
| EP2368579A1 (en) | 2004-01-21 | 2011-09-28 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| CN101098883B (zh) | 2004-12-23 | 2013-01-23 | 诺和诺德医疗保健公司 | 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| US20080188400A1 (en) * | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
| JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
| JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| EP2059527B1 (en) | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
| WO2008078189A2 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
| WO2008127702A2 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| AU2008345231B2 (en) | 2007-12-27 | 2014-09-11 | Takeda Pharmaceutical Company Limited | Cell culture processes |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| ES2966234T3 (es) | 2009-06-09 | 2024-04-18 | Prolong Pharmaceuticals Llc | Composiciones de hemoglobina |
| WO2011074578A1 (ja) * | 2009-12-14 | 2011-06-23 | 国立大学法人北海道大学 | 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| US9145552B2 (en) | 2012-07-25 | 2015-09-29 | Catalyst Biosciences, Inc. | Modified factor X polypeptides and uses thereof |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT87688B (pt) * | 1987-06-12 | 1992-09-30 | Hoechst Japan | Processo para a preparacao de proteina hibrida c |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| CA2074839C (en) * | 1990-01-29 | 2000-11-14 | Kathleen L. Berkner | Modified factor vii anticoagulant proteins |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Ceased
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Ceased
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
| JP2001520042A5 (es) | ||
| Sadler | Thrombomodulin structure and function | |
| KR870002848A (ko) | 항응고물질, 그 제조방법 및 이물질을 유효 성분으로 포함하는 항응고제 | |
| ATE342962T1 (de) | Zusammensetzungen und verfahren für verbesserte zellkultur | |
| PT1003560E (pt) | Radioprotector para peptidos marcados com radioisotopos | |
| BRPI0014076B8 (pt) | benzamidas e inibidores correlatos do fator xa | |
| ATE506071T1 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
| ATE500323T1 (de) | Subtilisin-variante | |
| EP1548032A4 (en) | KDR-PEPTIDES AND VACCINES CONTAINING THEM | |
| PT883687E (pt) | Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes | |
| WO2003012050A3 (en) | Mitochondrial genome replenishment | |
| BR0108959A (pt) | Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico | |
| ES2094111T3 (es) | Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen. | |
| TR200002179T2 (tr) | Kristalin teriparatid. | |
| DE3484616D1 (de) | Enzymwiderstandsfaehige immunomodulatorische peptide. | |
| Xiao et al. | Phosphorylation of HMG‐I by Protein Kinase C Attenuates Its Binding Affinity to the Promoter Regions of Protein Kinase C γ and Neurogranin/RC3 Genes | |
| ATE426028T1 (de) | Zellvolumenregulierte humane kinase h-sgk | |
| Bab et al. | Isolation of mitogenically active C‐terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| KR970707162A (ko) | II종 포스포리파제 A2 저해작용을 갖는 신규한 모노클로날 항체 및 그 일부를 포함하는 단백질(Novel monoclonal antibody having inhibitory effect on type II phospholipase A2 and protein containing a part of the same) | |
| DK1276763T3 (da) | Anti-fryseproteiner, deres fremstilling og anvendelse | |
| LTIP610A (en) | Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds | |
| BR0009396A (pt) | Lipase, composição detergente, sequência de dna, vetor de expressão, célula hospedeira transformada, e, processo para produzir a lipase | |
| DE59712235D1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |